Abstract Purpose: To describe the Food and Drug Administration (FDA) review and approval
of erlotinib (Tarceva, OSI Pharmaceuticals, Melville, NY) for treatment of patients with locally …

7022 Background: In phase II studies, erlotinib has shown single agent activity in a number
of tumor types, including NSCLC. NCIC CTG BR. 21 is a randomized, placebo-controlled …

BACKGROUND. Preclinical studies have suggested that erlotinib at high doses may inhibit
additional sites downstream of the epidermal growth factor receptor (EGFR), resulting in …

Background We conducted a randomized, placebo-controlled, double-blind trial to
determine whether the epidermal growth factor receptor inhibitor erlotinib prolongs survival …

Introduction: Erlotinib is a small molecule inhibitor of epidermal growth factor receptor
tyrosine-kinase activity that has been shown to significantly increase survival for patients …

Abstract On November 18, 2004, erlotinib (Tarceva®; OSI Pharmaceuticals, Inc., Melville,
NY, http://www. osip. com, and Genentech, Inc., South San Francisco, CA, http://www. gene …

Purpose Erlotinib is a potent inhibitor of the epidermal growth factor receptor tyrosine kinase,
with single-agent antitumor activity. Preclinically, erlotinib enhanced the cytotoxicity of …

Purpose Erlotinib is a highly specific epidermal growth factor receptor (HER1/EGFR)
tyrosine kinase inhibitor. This phase II study of erlotinib in patients with HER1/EGFR …

Although treatment with cytotoxic agents has produced modest survival improvement in
patients with stage III and IV non-small cell lung cancer (NSCLC), it appears that a plateau …

Introduction Currently, the inhibitor of the epidermal growth factor receptor tyrosine kinase
erlotinib is widely used for the treatment of non-small cell lung cancer. Patients with a …